PD-L1 Inhibitor Combination Triples Complete Response Rates in Advanced Oral Cancer

Can Immunotherapy Redefine Treatment Strategies in HNSCC?

The treatment landscape for locally advanced head and neck squamous cell carcinoma (HNSCC) continues to evolve, with emerging evidence supporting novel immunotherapeutic approaches. A recent phase II clinical trial has demonstrated promising results for a PD-L1 inhibitor combined with chemotherapy in patients with locally advanced oral squamous cell carcinoma (OSCC), potentially offering a new therapeutic avenue for this challenging disease. The single-arm study evaluated the efficacy and safety of adebrelimab, a humanized monoclonal antibody targeting PD-L1, in combination with albumin-bound paclitaxel and carboplatin in patients with resectable locally advanced OSCC. With head and neck cancer ranking among the top 10 cancers globally in terms of incidence according to the International Agency for Research on Cancer, these findings represent a significant step forward in addressing the persistent challenges of recurrence, distant metastasis, and mortality that plague patients despite aggressive multimodal therapy. The study's primary endpoint focused on pathological complete response (PCR), with secondary endpoints examining objective response rate (ORR), major pathological response (MPR), disease-free survival, and overall survival rates.

The trial enrolled 30 patients with locally advanced OSCC between October 2023 and December 2024, with a median age of 52 years. The cohort predominantly consisted of male patients (76.7%), with tongue cancer being the most common tumor site (60%), followed by buccal cancer (20%) and gingival cancer (13.3%). In terms of disease staging, 63.3% of patients had stage III tumors, while 36.7% had stage IVA disease. All patients received intravenous infusions of albumin-bound paclitaxel (260 mg/m²), carboplatin (AUC = 5), and adebrelimab (1200 mg) on the first day of each 3-week cycle for a total of three cycles. Following completion of the neoadjuvant regimen, patients underwent surgical intervention 21 days after the final cycle, with adjuvant radiotherapy or chemotherapy administered based on postoperative pathological staging. Throughout the treatment period, patients underwent comprehensive monitoring for adverse events, which were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Additionally, magnetic resonance imaging (MRI) was performed before treatment initiation and after completing the three cycles to evaluate treatment response according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Postoperative pathological specimens were carefully examined to determine the presence and proportion of residual viable tumor cells, allowing for precise assessment of treatment efficacy.

What Are the Efficacy and Safety Outcomes of the Novel Regimen?

The study's findings reveal impressive efficacy outcomes for the combination regimen. Among the 28 patients who completed the full treatment course, the objective response rate (ORR) reached 60.7% (95% CI: 40.58-78.50%), with 15 patients (53.6%) achieving a partial response and 2 patients (7.1%) attaining a complete response according to imaging criteria. More significantly, pathological evaluation demonstrated a pathological complete response (PCR) rate of 35.7% (95% CI: 18.64-55.93%), substantially higher than the approximately 13.4% historically observed with traditional neoadjuvant chemotherapy regimens like TPF (docetaxel, cisplatin, and 5-fluorouracil). Furthermore, 64.3% of patients (95% CI: 44.07-81.36%) achieved a major pathological response (MPR), defined as ≤10% viable tumor cells in the primary lesion specimen. The clinical to pathological downstaging rate was particularly impressive at 71.4% (95% CI: 51.33-86.78%), and R0 resection was achieved in all patients who underwent surgery (28/28, 100%). These findings underscore the potential of PD-L1 inhibition combined with chemotherapy to significantly improve pathological responses and surgical outcomes in patients with locally advanced OSCC, potentially translating to improved long-term survival and reduced recurrence rates, though longer follow-up is needed to confirm these outcomes.

The safety profile of the combination regimen proved manageable, with most adverse events being mild to moderate in severity. All patients experienced some form of treatment-related adverse event, with alopecia (100%), anemia (80%), fatigue (23.3%), pruritus (16.7%), and hyperthyroidism (6.7%) being the most frequently reported. Importantly, only one patient (3.3%) developed grade 3-4 adverse events, specifically liver failure after the first cycle, leading to discontinuation of the study medication. This patient received appropriate management with methylprednisolone and liver-protective agents, resulting in normalization of liver function within one month. The patient subsequently underwent successful radical surgery for oral cancer and was discharged after recovery. The timing of adverse events provided valuable insights into their etiology, with alopecia and anemia typically occurring within the first week post-treatment, suggesting these were primarily attributable to the chemotherapy components. In contrast, immune-related adverse events such as hyperthyroidism and pruritus emerged later, typically during weeks 2-3, consistent with the characteristic delayed onset of immune checkpoint inhibitor-associated toxicities. Notably, no grade 3 or 4 surgical complications were observed among patients who underwent surgery, and the average postoperative hospital stay was 8.1 days, with no patients experiencing prolonged hospitalization due to severe postoperative complications.

Why Do Imaging and Biomarker Assessments Differ in Evaluating Response?

An interesting finding from this study was the observed discrepancy between the objective response rate as assessed by imaging (60.7%) and the pathological complete response rate (35.7%), highlighting certain limitations of conventional imaging modalities in accurately reflecting the true extent of tumor response to immunotherapy. This discordance likely stems from the unique mechanisms of action of immunotherapy, which can lead to pseudoprogression due to immune cell infiltration mimicking tumor growth or tumor fibrosis despite the absence of viable malignant cells. Additionally, immunotherapy induces profound remodeling of the tumor microenvironment characterized by lymphocyte infiltration, necrosis, and inflammation, which may not be adequately captured by conventional imaging criteria that primarily focus on tumor size reduction. This observation underscores the critical importance of incorporating both radiographic and pathological assessments in evaluating treatment response to immunotherapy-based regimens. Pathological complete response serves as a more robust predictor of long-term survival outcomes, particularly in the neoadjuvant setting, as it directly assesses tumor eradication at the cellular level rather than relying on potentially misleading imaging findings that may reflect treatment-related inflammatory changes rather than true antitumor activity.

The study also explored potential correlations between PD-L1 expression levels and treatment response, though no statistically significant association was identified between the combined positive score (CPS) stratification (≤20 vs. >20) and pathological response categories. While patients with CPS ≥20 showed a numerically higher PCR/MPR rate (66.67% vs. 61.11%), this difference did not reach statistical significance, possibly due to the limited sample size and insufficient statistical power. Further analysis revealed that among patients who achieved a PCR, only 20% had systemic comorbidities such as hypertension and diabetes, whereas this proportion was significantly higher (50%) in patients with a partial pathological response or no pathological response, suggesting that underlying systemic diseases may adversely impact the likelihood of achieving optimal treatment outcomes. These observations highlight the complex interplay between tumor biology, patient characteristics, and treatment response, emphasizing the need for larger studies with comprehensive biomarker analyses to identify reliable predictors of response to immunotherapy-based regimens in OSCC.

Could These Innovations Transform Future Clinical Practice in OSCC?

The durability of treatment response represents another intriguing aspect of this study. In one notable case, a patient who refused surgery after completing the three treatment cycles exhibited continued tumor regression for 4 months following treatment cessation, suggesting potential persistent immunological activity or delayed treatment effects. However, the study also documented two instances of disease recurrence during the follow-up period. One patient with pathologically confirmed pN0 status developed cervical lymph node recurrence 4 months post-surgery despite receiving postoperative maintenance monotherapy, potentially due to occult micrometastases undetected by conventional pathology or immune escape mechanisms. Another patient with pathologically confirmed lymph node metastasis who declined adjuvant radiotherapy experienced recurrence 7 months postoperatively, likely due to inadequate local control and insufficient systemic treatment intensity. These cases highlight the importance of comprehensive treatment approaches, improved micrometastasis detection methods, and patient compliance with recommended adjuvant therapies to optimize outcomes in locally advanced OSCC. With a median follow-up of 295.5 days as of February 2025, all 30 patients remained alive, though the 2-year disease-free survival and overall survival rates are yet to be determined as follow-up continues.

This pioneering study represents the first report on the therapeutic efficacy of a PD-L1 inhibitor (adebrelimab) combined with chemotherapy for locally advanced OSCC, establishing a foundation for future phase III randomized controlled trials. While the single-arm design has inherent limitations, it provides valuable preliminary data on the efficacy and safety of this novel combination approach. The study's findings suggest that PD-L1 inhibition in conjunction with standard chemotherapy could potentially transform the treatment landscape for locally advanced OSCC, offering improved pathological responses, successful downstaging, and potentially enhanced long-term survival outcomes. However, several questions remain unanswered and warrant further investigation. Could the timing and duration of neoadjuvant immunochemotherapy be optimized to maximize efficacy while minimizing toxicity? Might certain molecular or immunological biomarkers beyond PD-L1 expression more reliably predict which patients are most likely to benefit from this approach? How does this regimen compare with other emerging neoadjuvant strategies, such as those incorporating different immunotherapy agents or targeted therapies? Addressing these questions through larger, randomized trials with longer follow-up periods will be essential to fully establish the role of PD-L1 inhibitors in the management of locally advanced OSCC and potentially reshape treatment guidelines for this challenging disease.

The implications of these findings extend beyond clinical practice to influence future research directions in head and neck oncology. The observed discrepancy between imaging-based and pathological responses highlights the need for refined response assessment criteria specifically tailored to immunotherapy-based regimens. Additionally, the identification of potential predictive biomarkers and patient characteristics associated with optimal treatment outcomes could pave the way for more personalized treatment approaches in OSCC. As the field continues to evolve, integration of novel technologies such as liquid biopsies, artificial intelligence-assisted imaging analysis, and comprehensive genomic profiling may further enhance our ability to select patients most likely to benefit from immunotherapy-based approaches and monitor treatment response in real-time. Could the combination of PD-L1 inhibitors with other immunomodulatory agents or targeted therapies yield even more impressive outcomes in specific molecular subtypes of OSCC? How might the neoadjuvant immunochemotherapy paradigm be extended to other head and neck cancer subsites or disease stages? These questions represent exciting avenues for future investigation as the oncology community works to optimize treatment strategies and improve outcomes for patients with this challenging disease.

Summary

A recent phase II clinical trial has demonstrated promising results for combining the PD-L1 inhibitor adebrelimab with chemotherapy in patients with locally advanced oral squamous cell carcinoma (OSCC). The study enrolled 30 patients who received neoadjuvant treatment with adebrelimab, albumin-bound paclitaxel, and carboplatin for three cycles, followed by surgical resection. The primary endpoint of pathological complete response (PCR) was achieved in 35.7% of patients, substantially higher than the approximately 13.4% historically observed with traditional neoadjuvant chemotherapy. Additionally, 64.3% of patients achieved a major pathological response, and the objective response rate based on imaging was 60.7%. Clinical to pathological downstaging occurred in 71.4% of patients, and complete tumor resection (R0) was achieved in all surgical cases. The safety profile was manageable, with most adverse events being mild to moderate, including alopecia, anemia, and fatigue. Only one patient experienced grade 3-4 adverse events, specifically liver failure, which resolved with appropriate management. An interesting finding was the discrepancy between imaging-based and pathological responses, highlighting limitations of conventional imaging in accurately assessing immunotherapy efficacy. The study found no significant correlation between PD-L1 expression levels and treatment response, though patients with fewer systemic comorbidities appeared more likely to achieve optimal outcomes. With a median follow-up of 295.5 days, all patients remained alive, though longer follow-up is needed to determine disease-free and overall survival rates. This study represents the first report on PD-L1 inhibition combined with chemotherapy for locally advanced OSCC and provides a foundation for future randomized controlled trials to establish the role of this approach in clinical practice.